Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • IRAK1/4
      • RIPK1
      • COVID-19
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Forma
      • Grifols
      • Kissei
      • Lilly
      • Medison
      • Knight
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Jul 09, 2009 6:00am EDT

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

Jul 08, 2009 9:00pm EDT

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis

Jun 10, 2009 7:30am EDT

Rigel to Present at Jefferies Healthcare Conference

Jun 01, 2009 7:30am EDT

Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers

May 13, 2009 7:30am EDT

Rigel to Present at JMP Securities Research Conference

May 05, 2009 7:00am EDT

Rigel Announces First Quarter 2009 Financial Results

Feb 24, 2009 6:00am EST

Rigel Announces Fourth Quarter and Year End 2008 Financial Results

Feb 05, 2009 7:30am EST

Rigel to Present at BIO CEO & Investor Conference

Feb 03, 2009 6:00am EST

Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results

Feb 02, 2009 6:00pm EST

Rigel to Host Conference Call on February 3, 2009

  • Previous
  • 1…
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • …36
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2023 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

REZLIDHIA is a trademark of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin